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Abstract: Eltrombopag is one of a number of novel agents recently developed for use in the 
treatment of patients with immune thrombocytopenia (ITP). Rather than preventing destruction 
of platelets, these agents increase the production of platelets, presumably overwhelming the 
immune system resulting in normal platelet counts in individuals refractory to or dependent on 
other therapies. These treatments are well tolerated and in randomized controlled trials show an 
improvement in platelet counts and a reduction in bleeding in refractory patients. This article 
summarizes the development of this new class of drug and evaluates the safety and efficacy of 
eltrombopag in patients with ITP.
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Introduction
Immune thrombocytopenia (ITP) is an acquired disease of low platelet counts (less 
than 100 × 109/L) with no clear initiating or underlying cause. ITP may manifest with 
bleeding symptoms which correlate, to some extent, with the severity of thrombocy-
topenia. The majority of cases are considered primary, where a precipitating cause is 
unknown, whereas others are attributed as secondary to coexisting medical conditions 
such as systemic lupus erythematosus, chronic lymphocytic leukemia, and immune 
deficiency disorders. Although the definition of chronic ITP has been debated, a recent 
consensus statement suggests this should be considered if platelets remain below 
normal for more than 12 months.1
The pathogenesis of ITP is complex but involves premature destruction of platelets 
mediated by anti-platelet antibodies2 and/or by direct T cell mediated platelet lysis.3 In 
addition to increased platelet destruction, there is also evidence of decreased platelet 
production. In 1989, Gernsheimer et al4 described inappropriately normal or decreased 
platelet production in some patients with ITP. Further studies have shown increased 
apoptosis in megakaryocytes in patients with ITP5 and CD34+ cells grown with plasma 
from patients with ITP have impaired development of megakaryocytes and production 
of platelets suggesting that the anti-platelet antibody not only results in premature 
destruction of platelets but also impairs platelet production.2
Treatment aims in ITP have previously concentrated on preventing platelet destruc-
tion using steroids, immunoglobulins, immunosuppressive agents and splenectomy.6,7 
However, many of these treatments are unsatisfactory with the morbidity and mortality 
of this disorder relating as much from the side effects of treatment such as infections as 
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from bleeding.6 Novel treatment strategies that do not include 
immunosuppression are needed. Following the understand-
ing of the role of megakaryocytes in the pathogenesis of ITP, 
and the appreciation of the low level of platelet production 
in patients with ITP, the potential use of agents with throm-
bopoietic ability in ITP has been explored.
This review will focus on the development and therapeutic 
use of one of these agents eltrombopag, in chronic ITP.
Thrombopoiesis
Over the last 25 years a number of hemopoietic growth 
factors with thrombopoietic activity have been identi-
fied including granulocyte-macrophage colony stimulat-
ing factor (GM-CSF); stem cell factor (c-kit ligand); 
interleukin 1 (IL-1), IL-3, IL-6 and IL-11; and thrombo-
poietin (TPO).8–11,12 Gene-targeting studies have demon-
strated that TPO, the c-MPL ligand, is the most important 
physiologic regulator of steady-state megakaryocyte and 
platelet production.13,14
TPO and its biology
TPO is a large molecule (95 KDa) synthesized primarily in 
the liver as a single 333-amino acid precursor protein. The 
receptor binding domain of TPO contains 153 amino-terminal 
residues: Each TPO molecule binds two TPO receptors, one 
via a high-affinity binding site (13 amino acids) and the other 
via a low affinity binding site (11 amino acids).15 Binding of 
TPO to its receptor triggers the activation of the cytoplasmic 
tyrosine kinases janus kinase (JAK)2 and subsequent signal 
transducers and activators (STAT)5, phosphoinositide-3 
kinase and Ras-mitogen-activated protein kinase (MAPK). 
Activation of these pathways leads to changes in gene expres-
sion that promote progression along the megakaryocytic 
pathway, ultimately leading to the release of platelets into 
the peripheral circulation (Figure 1).16
The TPO receptor is found on megakaryocyte precursor 
cells, megakaryocytes, and platelets, as well as on stem cells 
and early bone marrow progenitor cells of all lineages.
Physiologic control of TPO 
production
There are no known physiologic sensors of the platelet count 
or mass and studies have suggested that hepatic transcription 
and translation of the TPO gene to be constant.17,18 TPO is 
cleared by avid TPO receptors present on platelets and pos-
sibly megakaryocytes. Significantly elevated endogenous 
TPO levels have been observed in disorders in which there 
is diminished platelet production and therefore reduced TPO 
clearance, although thrombopoietin levels are typically nor-
mal in patients with ITP. During times of normal or increased 
platelet mass there is increased clearance of TPO leading to 
normalization of TPO levels.19,20
First-generation recombinant 
thrombopoietin
Since TPO was cloned in 1994 several TPO molecules 
have been developed for clinical evaluation. The first 
generation recombinant TPOs, recombinant human 
thrombopoietin (rh TPO) and pegylated human recom-
binant megakaryocyte growth and development factor 
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Figure 1  TPO binds the distal part of the inactive TPO (cMPL) receptor and creates an activated receptor that initiates many downstream signal transduction events 
( JAK STAT and mitogen activated protein kinase signal pathways) whereas eltrombopag interacts with the transmembrane domain of c-MPL. reproduced with permission 
from Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11): 4607–4616.46 Copyright © 2007 The American Society of Hematology.Drug Design, Development and Therapy 2010:4 141
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(PEG-rHuMGDF), developed in 1995 have undergone 
considerable preclinical and clinical studies. Platelet 
count response to single dose administration of both 
recombinant TPOs was demonstrated. A 5-day time lag 
occurred, presumably due to TPO stimulation of early and 
not late megakaryocyte precursors, with a peak platelet 
count at 12 to 14 days, a log-linear dose response curve 
and a return to baseline platelet count by day 28 with no 
rebound thrombocytopenia.21,22
Promising clinical trial results were seen in the areas 
of chemotherapy-induced thrombocytopenia, stem cell 
transplantation, myelodysplastic syndromes21,23–28 and prior 
to platelet apheresis.29 Recombinant TPO also showed effi-
cacy in patients with immune thrombocytopenia (ITP);30 
platelet counts rose dramatically in 3 of 4 patients who had 
received 7 daily treatments with PEG-rHuMGDF. Follow-
ing on from these promising clinical trial results a large 
safety study of PEG-rHuMGDF was undertaken in healthy 
volunteers.31 Each volunteer was given a monthly dose 
of either PEG-rHuMGDF or placebo for up to 3 months. 
However, 13 of 535 subjects who received PEG-rHuMGDF 
developed an anti-TPO antibody compared with none of 
the 532 placebo-treated subjects. This antibody was later 
found to be an IgG4 subclass and was cross reactive with 
endogenous TPO neutralizing its activity and resulting in 
severe thrombocytopenia (platelet counts 10 to 20 × 109/L). 
In 2 patients pancytopenia developed and some volunteers 
required treatment with ciclosporin and rituximab to 
eliminate the autoantibody and restore normal blood counts. 
All volunteers subsequently recovered.22,31 Subsequent 
analysis of 650 cancer chemotherapy patients treated with 
PEG-rHuMGDF identified at least four who also developed 
thrombocytopenia, believed to be due to auto-antibody 
formation. No subject treated with rhTPO developed neu-
tralizing antibodies. However, clinical development of both 
recombinant TPOs was ultimately discontinued and many 
of the clinical studies undertaken between 1994 and 1999 
remain unpublished.15
Alternative TPO agonists
Due to the promising platelet responses of the first-genera-
tion agents, there has been focus on the development of safe 
nonimmunogenic growth factors. These can be considered in 3 
classes: TPO nonpeptide mimetics, TPO peptide mimetics and 
TPO antibody mimetics. Each class has a unique structure and 
therefore a unique mode of activation of the TPO receptor. This 
review article focuses on eltrombopag, the most extensively 
trialled drug of the TPO nonpeptide mimetic class.
Eltrombopag (SB497115)
Eltrombopag was first developed by Duffy et al following 
the screening of libraries of small molecules using an assay 
to identify structures that stimulate the TPO receptor-linked 
transduction pathways.32,33 The libraries of small compounds 
underwent further biological modification prior to entering 
clinical trials with the sulfonate group being replaced by a 
biphenyl carboxylate compound in order to yield higher oral 
bioavailability.34
This class of molecule has several important characteris-
tics: Firstly it is extremely small (564.6 Da) and binds very 
precisely to the TPO receptor. Secondly it is only able to do 
this in humans and non-human primates,34 preventing efficacy 
studies in other animal models. The species specificity is due 
to the amino acid present at position 499 in the TPO receptor 
transmembrane region (histidine in primates and leucine in 
all other species). Thirdly eltrombopag appears to activate 
the TPO receptor by binding to the transmembrane domain 
unlike TPO (and TPO peptide mimetics) which bind to the 
distal homology receptor domain.
Eltrombopag has high potency in in vitro assays for 
activation of the STAT and MAPK signaling pathways. 
It activates TPO receptor with kinetics similar to rhTPO 
resulting in proliferation of TPO-dependent cell lines 
and induces the differentiation of bone marrow precursor 
cells. These activities of eltrombopag have been shown to 
be dependent on the expression of TPO receptor. Because 
eltrombopag does not bind to the same site on TPO receptor 
as TPO this prevents competitive binding and allows eltrom-
bopag and TPO to have additive cell-signaling effects.34
Clinical studies with eltrombopag
Phase 1 clinical trials of an oral once daily capsule given to 
73 healthy volunteers were first reported in 2007.35 A dose-
dependent increase in platelet count at doses of 30 mg or more 
given daily for 10 days was reported, with no adverse events. 
Furthermore, there was no evidence of rebound thrombo-
cytopenia following discontinuation of treatment. Platelet 
function, as measured by platelet aggregation and activation, 
was not affected by the administration of eltrombopag.35
Following the success of these phase I studies, 
Eltrombopag is being studied at phase I/II and phase III in 
ITP, chemotherapy-induced thrombocytopenia, myelodys-
plastic syndrome (MDS) and hepatitis C infection.
Chronic iTP
A phase I/II study of 118 patients (in 44 centers) with refrac-
tory or relapsed chronic ITP was reported in 2007. This study Drug Design, Development and Therapy 2010:4 142
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enrolled patients in a randomized, double blind, placebo-
controlled study to receive either placebo or eltrombopag at 
30-mg, 50-mg, or 75-mg doses (in a 1:1:1:1 ratio) for 6 weeks. 
The primary endpoint was a platelet count above 50 × 109/L 
on day 43. Randomization was stratified for concomitant 
steroid use, previous splenectomy and baseline platelet count. 
Eltrombopag was well tolerated and achieved dose related 
responses; the percentage of patients with a platelet count 
above 50 × 109/L on day 43 were 11%, 28%, 70% and 81% 
for the placebo, 30 mg, 50 mg and 75 mg doses respectively. 
The median platelet counts on day 43 for the groups receiving 
30, 50, and 75 mg of eltrombopag were 26 × 109/L, 128 × 
109/L, and 183 × 109/L, respectively; for the placebo group 
the median platelet count was 16 × 109/L.
Significantly, this trial demonstrated a decreased bleed-
ing tendency in those patients treated with higher doses of 
eltrombopag; by day 15 over 80% of patients on higher 
doses (50 mg and 75 mg) had an increased platelet count 
with significantly less bleeding: During the 6-week trial, the 
incidence of bleeding was 14%, 17%, 7% and 4% for the 
placebo, 30-mg, 50-mg and 75-mg doses respectively. 
The counts were maintained for the 6-week trial period but 
returned to baseline on stopping treatment in the majority of 
patients. In this study there was one reported death in a patient 
with multiple co-morbidities, not felt to be related to the use 
of eltrombopag. Eltrombopag was associated with minor 
adverse events (eg, headaches in 20%) and was well toler-
ated. There were no other definite treatment-related adverse 
events reported during the study. The incidence and severity 
of adverse events were similar for all four study groups.
In a following phase II study, patients enrolled in the initial 
6-week study were eligible to enter a long-term, open-label 
extension study – EXTEND study (Eltrombopag Extended 
Dosing Study). In this study, the drug was administered orally 
daily aiming for a target platelet count of 50 to 200 × 109/L, 
and with the intention that concurrent ITP medications 
(eg, corticosteroids) could be tapered. Interim analysis of 
89 evaluable subjects with a treatment duration of 151 days 
showed that of the 61 subjects (73%) with a baseline plate-
let count below 30 × 109/L, 43 achieved a platelet count of 
50 × 109/L. Most were able to maintain this platelet count 
elevation and showed a trend toward fewer bleeding events.36
Similar promising responses were reported in a multi-
national phase III randomized, placebo-controlled study of 
110 patients with chronic ITP.37 The purpose of this study was 
to evaluate the efficacy, safety and tolerability of once daily 
eltrombopag (50 mg) and to explore the efficacy of a dose 
escalation to 75 mg. Patients with platelet counts less than 
30 × 109/L were randomized to either placebo (37 patients) 
or oral eltrombopag 50 mg once daily (73 patients) in a 
1:2 ratio. Dose escalation to 75 mg once daily was allowed 
if the platelet count was less than 50 × 109/l at 3 weeks 
(33 of 74 patients). The primary endpoint was the number 
of patients with a platelet count 50 × 109/L at day 43. 
At 6 weeks, the primary endpoint had been reached in 
6 (16%) placebo and 43 (59%) eltrombopag treated patients. 
Response was not affected by predefined study stratification 
variables (baseline platelet count, previous splenectomy, con-
comitant ITP drugs) or by the number of previous treatments. 
In addition the bleeding incidence was significantly lower 
in the eltrombopag group with WHO grade 2–4 bleeding 
observed in 16% of patients compared with 36% of placebo 
patients (odds ratio 0.49 [95% confidence interval 0.26 to 
0.89] P = 0.021). Again adverse events were infrequent with 
no significant differences between the two groups. Slight 
increases of liver enzymes were noted in 6 patients in the 
eltrombopag group. Cataracts were closely monitored during 
the study due to concerns raised in preclinical rodent studies 
but no excess risk has been identified in any trial.37
Antiplatelet antibodies and thrombopoietin levels were 
not assessed in these patients and it is unclear what effect 
these variables will have on response to treatment. It has, 
however, been suggested that thrombopoietic agents such 
as eltrombopag may result in improved immune regulation 
by regulatory T cells and these agents may restore immune 
tolerance.38
Quality of life
The impact of eltrombopag on quality of life in chronic ITP 
was evaluated in both the phase II and III study with no sig-
nificant difference found between placebo and treatment arms 
and between responders and non-responders over the 6-week 
time period.37 This is possibly due to the short follow-up and 
small sample size for this secondary endpoint.
Health related questionnaires are now incorporated into a 
number of the more recent clinical trials. In a survey completed 
by 1542 respondents with chronic ITP, patients were willing 
to accept significant risks of thromboembolic events, liver 
abnormalities, and rebound thrombocytopenia for greater effi-
cacy benefit, as well as to avoid the use of corticosteroids.39
Hepatitis C related thrombocytopenia
McHutchison and colleagues reported in 2007 the results of a 
multicenter, randomized, blinded, placebo-controlled phase II 
trial of eltrombopag versus placebo in 74 patients with chronic 
hepatitis C infection who had compensated liver disease with a Drug Design, Development and Therapy 2010:4 143
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platelet count 20 to 70 × 109/L. These patients were randomized 
to eltrombopag (30 mg, 50 mg, or 75 mg daily) or placebo daily 
for 4 weeks. All patients who completed 4 weeks of treatment 
and reached a platelet count of 70 × 109/L received antiviral 
therapy (pegylated interferon with ribavarin) concomitant with 
eltrombopag for 8 to 12 weeks.
The results showed that none of the patients in the placebo 
arm reached the primary end point; however 20 of 23 patients 
receiving 75 mg eltrombopag attained a platelet count 100 × 
109/L. Compared with only 6% of the placebo group, 15 of 23 
patients (or 65%) in the high-dose eltrombopag group were 
able to complete 12 weeks of antiviral treatment without dose 
interruptions because they had platelets 50 × 109/L.
The most frequent adverse event in the 4 week eltrombopag 
phase was headache, reported by 3 patients on placebo, and 
5, 3, and 4 patients on eltrombopag 30 mg, 50 mg, and 75 mg, 
respectively. There are no safety concerns to date, although 
the combined numbers of patients treated are, to date, only in 
the hundreds. Phase III clinical trials evaluating eltrombopag 
in hepatitis C infection are in progress. Together they have a 
target enrolment of over one thousand patients.40
Potential serious adverse effects
Eltrombopag appears to have very good short-term toler-
ability with no serious adverse events reported. However, 
this drug has only been used in hundreds of patients and the 
maximum duration of treatment with eltrombopag reported 
is 151 days.15 Potential adverse effects include:
Antibody formation
There have been no reports of antibody formation (there is 
no sequence homology with TPO).
Thrombosis or thrombocytosis
It has been suggested that ITP (and/or its treatment) 
creates a prothrombotic state, possibly due to the large 
number of new (and active) platelets being formed. In the 
placebo-controlled ITP studies there has been no difference 
reported in thrombotic events between treatment or placebo 
arms.15 A comparative analyses of eltrombopag and TPO 
on in vitro platelet function demonstrated that eltrombopag 
stimulates platelet signal transduction with little or no 
effect on overall platelet function, in contrast to TPO, which 
significantly primes platelet activation.41
rebound thrombocytopenia
In the phase III trial of chronic ITP in over 100 patients, plate-
let counts remained above 50 × 10 9/L in approximately half 
the patients for a week following discontinuation. They gener-
ally returned to baseline levels within 2 weeks of discontinu-
ing therapy. In 2 patients recurrence of bleeding symptoms 
occurred with a decrease in platelet counts to 10 × 109/L 
and at least 10 × 109/L lower than baseline value.37
Reticulin fibrosis
Bone marrow (BM) reticulin (without collagen fibrosis) may 
be increased in patients with ITP. The presence of grade 1/2 
reticulin was reported in the BM of up to 67% of patients 
with ITP.42 Reticulin is a normal component of the bone 
marrow and is commonly seen in patients with autoimmune 
disorders. This is reversible, quite unlike collagen fibrosis. 
Bone marrow examination was not a requirement of the ran-
domized clinical trials. However of 117 ITP patients exposed 
to eltrombopag, 19 had bone marrow examinations (after a 
median of 13 months of various treatments) and seven showed 
fibrosis (5 reticulin and 2 collagen).15
A recent analysis of bone marrow biopsy reports in patients 
within EXTEND, REPEAT and RAISE clinical trials has been 
reported in abstract form. The reports of bone marrow biopsies 
performed at any time prior to eltrombopag exposure were 
reviewed. In the EXTEND study participants underwent bone 
marrow biopsy after one year on treatment and these reports 
were compared. There was no evidence of clinically relevant 
BM abnormalities or clinical findings typically associated 
with myelofibrosis in patients treated for up to 18 months 
with eltrombopag. Systematic longitudinal evaluation of bone 
marrows in EXTEND will provide meaningful data on the 
incidence of fibrosis during long-term treatment.43
increase in myeloblasts
Myelodysplastic syndrome is a clonal disorder with a pro-
pensity to malignant transformation, usually to acute myeloid 
leukemia. Malignant hemopoietic cells are known to express 
TPO receptors and there is a theoretical risk that TPO growth 
factors may stimulate growth of malignant cells. However the 
first generation TPOs used in patients with AML did not show 
any increase in blast percentage or relapse rates.44 At present 
there has been no reported case of increased blasts following 
the use of eltrombopag. Equally there have been no reports 
of stimulation of solid tumors in any trials. In vitro effects 
of eltrombopag on proliferation, apoptosis, differentiation, 
colony formation, and malignant self-renewal of bone mar-
row mononuclear cells (BM-MNC) of patients with AML 
and MDS have however been assessed. Malignant BM-MNC 
did not show increased proliferation, or increased clonogenic 
capacity at concentrations of eltrombopag ranging from 0.1 to 
30 µg/mL in vitro. Furthermore, eltrombopag was capable of Drug Design, Development and Therapy 2010:4 144
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increasing megakaryocytic differentiation and formation of 
normal megakaryocytic colonies from cultured cells of patients 
with AML and MDS.45
Conclusion
The successful use of eltrombopag in patients with chronic 
and often refractory ITP shows promise for this agent. At 
present eltrombopag has been licensed for use in ITP by 
the FDA and MHRA. It is available as 25-mg, 50-mg, or 
75-mg tablets administered orally once daily. Since food 
and divalent cations affect absorption, recipients should not 
eat food 2 hours before or after ingesting eltrombopag, and 
medications with divalent cations (eg, antacids or calcium) 
should not be taken. An important limitation of eltrombopag 
treatment is the time delay to platelet response (presumed 
secondary to the kinetics of stimulating platelet production) 
precluding its use in the management of acute bleeding when 
an urgent platelet increase is required.
Because the long term adverse events remain unknown, 
its current use may initially be restricted to the treatment 
of chronic ITP. We await the reporting of the long-term 
extension study in progress and postmarketing surveil-
lance in ITP should provide further information. Given the 
unknown long-term safety of eltrombopag this re-opens 
the debate as to whom we should be treating with chronic 
ITP. Should we treat the absolute platelet count or just the 
patient who bleeds? It is unclear whether bleeding pro-
pensity correlates with platelet size, maturity or specific 
activity. Disease modifiers (eg, platelet granule content) 
have not been identified.
At present the authors would support the use of eltrombopag 
for “third line” treatment of patients with persistent or chronic 
ITP. Typically such patients would have been refractory to pal-
liative treatments such as oral steroids and intravenous immuno-
globulin/anti D and would have usually been treated with either 
splenectomy and/or rituximab or other immunosuppressive agents 
such as mycophenolate mofetil, ciclosporin, and danazol. Whether 
this agent should be used before splenectomy is less obvious, par-
ticularly if long-term use is required to maintain platelet levels. If 
long-term safety studies and postmarketing surveilence continue 
to show admirable safety profiles with continued use, then these 
agents are likely to become more popular and given the poor toler-
ability of steroids and the concern over the use of blood products, 
these agents may in the future become the preferred therapy for 
patients with ITP, especially if short-term use can allow patients 
to go in to remission.
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